For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and the formulated version represents a true breakthrough . These groundbreaking therapies preserve the transthyretin protein, halting its destructive build-up and reducing the impact of the illness. Individuals are now repo